Navigation Links
Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
Date:7/22/2014

BETHLEHEM, Pa., July 22, 2014 /PRNewswire/ -- Eyeon Therapeutics has received a Notice of Allowance on a novel dry eye treatment based on a charged hydrophilic polymer developed at Particles Sciences, a leading drug delivery CDMO.  The product has been shown to be safe and effective in a small trial previously published.  Mark Mitchnick, MD, CEO states, "This first set of claims around the polymer and its class will go a long way to moving this technology into the commercial phase.  We have been using it in several development projects, and we believe it has promise in many ocular formulations as well as in other areas.  Helping Eyeon gain a proprietary position in this very important market is a great example of what Particle Sciences offers its partners." 

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "Dry eye is a serious and growing problem for which there are few therapies.  Our product offers a unique approach that is clinically validated and useful in a number of ocular applications.  In the coming months we will be pursuing partnerships and expanded protection around this product and follow-ons." 

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information.

Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at dave@eyeontherapeutics.com

Contact:
Maureen Grieco
610-861-4701
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Measuring Systems® Celebrates 40 Years of Leadership
2. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
3. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
4. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
5. Varian Medical Systems Signs Purchase Agreement with Advanced Particle Therapy LLC to Supply Technology for the Georgia Proton Treatment Center to be operated by Emory Healthcare
6. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
7. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
8. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
9. Waters Introduces CORTECS Columns Featuring Solid-Core Particle Technology
10. HORIBA Scientific Launches New Raman ParticleFinder Software
11. The Japanese Embolization Particle Market Will Witness Significant Market Activity And Rapid Growth Due To New Product Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, ... development and joint health in horses at the immunologic level. , The scientifically-developed ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... ... ... The bar for just about everything—apparel, eyewear, cars and even phone cases—is ... and film stardom.(1) Not to be left out is that most desired of commodities, ... gamut from being encrusted with jewels and precious metals to, at the very least, ...
(Date:4/24/2017)... ... ... Sean Fay is the undisputed king of the infomercial. With clients as ... Foreman Grill (which sold more than 100 million units worldwide), he has created more ... due to changes in the broadcast media landscape, the once ever-present infomercial has gone ...
Breaking Medicine News(10 mins):